Literature DB >> 15056857

Inhibitory effects of the essential oil from SuHeXiang Wan on the central nervous system after inhalation.

Byung-Soo Koo1, Seung-Il Lee, Jeoung-Hee Ha, Dong-Ung Lee.   

Abstract

The present study was performed to evaluate the central nervous system inhibitory effects of the essential oil from SuHeXiang Wan (Storax pill), a prescription usually used for treating epilepsy in traditional Chinese medicine, on fragrance inhalation (aroma therapy). Preinhalation of the fragrance oil markedly delayed the appearance of pentylenetetrazole-induced convulsion, but showed weak activities on picrotoxin- and strychnine-induced convulsions, which implies this drug may inhibit the convulsion by GABAergic neuromodulation. This essential oil inhibited the binding of [(3)H]Ro15-1788, a selective antagonist for the benzodiazepine receptor and also the binding of [(3)H]flunitrazepam, a selective agonist for the receptor, in the presence of gamma-aminobutyric acid (GABA) and NaCl, showing a positive GABA shift, which suggested the strong possibility of the agonistic activity of the essential oil to the GABA/benzodiazepine receptor complex in rat cerebral cortices. Furthermore, inhalation inhibited the activity of GABA transaminase as the inhalation period was lengthened. The GABA level was significantly increased and glutamate content was significantly decreased in mouse brain by preinhalation of the essential oil. The above results suggest that the anticonvulsive effect of this essential oil can also originate from the enhancement of GABA level in the mouse brain, because convulsion depends partially on GABA concentration which can be properly preserved by inhibiting GABA transaminase. Fragrance inhalation progressively prolonged the pentobarbital-induced sleeping time as inhalation time was lengthened and inhibited brain lipid peroxidation, to which the anticonvulsive action is attributed; this also supported the above results, confirming the inhibitory effects of the essential oil of SuHeXiang Wan on the CNS via the GABAergic system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056857     DOI: 10.1248/bpb.27.515

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

1.  Unraveling the novel effects of aroma from small molecules in preventing hen egg white lysozyme amyloid fibril formation.

Authors:  Zahra Seraj; Arefeh Seyedarabi; Ali Akbar Saboury; Mehran Habibi-Rezaei; Shahin Ahmadian; Atiyeh Ghasemi
Journal:  PLoS One       Date:  2018-01-22       Impact factor: 3.240

Review 2.  Interaction of Plant Extracts with Central Nervous System Receptors.

Authors:  Kenneth Lundstrom; Huyen Thanh Pham; Long Doan Dinh
Journal:  Medicines (Basel)       Date:  2017-02-23

Review 3.  Terpenes from Forests and Human Health.

Authors:  Kyoung Sang Cho; Young-Ran Lim; Kyungho Lee; Jaeseok Lee; Jang Ho Lee; Im-Soon Lee
Journal:  Toxicol Res       Date:  2017-04-15

Review 4.  Essential Oils and Their Constituents Targeting the GABAergic System and Sodium Channels as Treatment of Neurological Diseases.

Authors:  Ze-Jun Wang; Thomas Heinbockel
Journal:  Molecules       Date:  2018-05-02       Impact factor: 4.411

5.  The aroma of TEMED as an activation and stabilizing signal for the antibacterial enzyme HEWL.

Authors:  Zahra Seraj; Shahin Ahmadian; Matthew R Groves; Arefeh Seyedarabi
Journal:  PLoS One       Date:  2020-05-19       Impact factor: 3.240

Review 6.  The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.

Authors:  Dan Zhang; Bing Zhang; Jin-Tao Lv; Ri-Na Sa; Xiao-Meng Zhang; Zhi-Jian Lin
Journal:  Pharmacol Res       Date:  2020-05-05       Impact factor: 7.658

7.  Unravelling the Novel Effects of Three Volatile Compounds in Preventing Fibril Formation of Disease Related Tau and α-Synuclein Proteins- Towards Identifying Candidate Aromatic Substances for Treating Neurodegenerative Diseases.

Authors:  Zahra Moeini; Zahra Seraj; Toktam Zohoorian Abootorabi; Mohammadreza Ashrafi-Kooshk; Gholamhossein Riazi; Ali Akbar Saboury; Arefeh Seyedarabi
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.